Edwards Lifesciences welcomes CMS update to Medicare TAVR coverage policy

Reuters2026/09/10 21:49

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Edwards Lifesciences welcomed CMS’ updated national coverage determination for TAVR, citing improved access and greater Heart Team flexibility.
Policy update seen as supporting faster evaluation and treatment for aortic stenosis, which Edwards linked to better outcomes and lower costs.
Implementation expected to take time; Edwards reiterated confidence in its previously issued 2026 financial guidance.
2027 and longer-term guidance slated for December at the company’s investor conference.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Edwards Lifesciences Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20260910286048) on September 10, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Edwards Lifesciences welcomes CMS update to Medicare TAVR coverage policy

You may also like

Crypto prices